Roberto Negro1, Roberto Attanasio2, Franco Grimaldi3, Rinaldo Guglielmi4, Enrico Papini4. 1. Division of Endocrinology, 'V. Fazzi' Hospital, Lecce, Italy. 2. Endocrinology Service, Galeazzi Institute IRCCS, Milan, Italy. 3. Endocrinology and Metabolic Disease Unit, Azienda Ospedaliero-Universitaria 'S. Maria della Misericordia', Udine, Italy. 4. Department of Endocrinology, Regina Apostolorum Hospital, Albano Laziale, Italy.
Abstract
BACKGROUND: Patients suffering from Graves' disease (GD) are quite frequent in endocrine clinical practice. In particular, overt hyperthyroidism may be complicated by serious adverse events and requires careful treatment, but its management has changed over the years in both the USA and European Union (EU). OBJECTIVES: To evaluate the current diagnosis and management of patient's with GD in Italy, and compare results with those obtained in previous similar surveys in the USA and EU. METHODS: Members of the Italian Association of Clinical Endocrinologists (AME) were asked to participate in a Web-based survey on management of GD. RESULTS: In total, 947 responses were obtained. The preferred diagnostic modality in Italy is TSH receptor antibody determination in conjunction with ultrasound, while radioactive iodine uptake/scan is preferred in the USA. Methimazole (MMI) 20-30 mg/day with a β-blocker is the initial treatment of choice in Italy and the EU, whereas the USA opts more frequently for radioactive therapy. If Graves' orbitopathy occurs, orbit CT/MRI scans are more often obtained in Italy and the EU than in the USA. In case of planned pregnancy in 6-12 months, surgery is more frequently suggested in Italy than in the EU and USA. Propylthiouracil is generally preferred to MMI in the first trimester. CONCLUSIONS: Italian endocrinologists have shown significantly different patterns in diagnosis and management of GD compared to both the USA and EU.
BACKGROUND:Patients suffering from Graves' disease (GD) are quite frequent in endocrine clinical practice. In particular, overt hyperthyroidism may be complicated by serious adverse events and requires careful treatment, but its management has changed over the years in both the USA and European Union (EU). OBJECTIVES: To evaluate the current diagnosis and management of patient's with GD in Italy, and compare results with those obtained in previous similar surveys in the USA and EU. METHODS: Members of the Italian Association of Clinical Endocrinologists (AME) were asked to participate in a Web-based survey on management of GD. RESULTS: In total, 947 responses were obtained. The preferred diagnostic modality in Italy is TSH receptor antibody determination in conjunction with ultrasound, while radioactive iodine uptake/scan is preferred in the USA. Methimazole (MMI) 20-30 mg/day with a β-blocker is the initial treatment of choice in Italy and the EU, whereas the USA opts more frequently for radioactive therapy. If Graves' orbitopathy occurs, orbit CT/MRI scans are more often obtained in Italy and the EU than in the USA. In case of planned pregnancy in 6-12 months, surgery is more frequently suggested in Italy than in the EU and USA. Propylthiouracil is generally preferred to MMI in the first trimester. CONCLUSIONS: Italian endocrinologists have shown significantly different patterns in diagnosis and management of GD compared to both the USA and EU.
Authors: Luigi Bartalena; Lelio Baldeschi; Alison Dickinson; Anja Eckstein; Pat Kendall-Taylor; Claudio Marcocci; Maarten Mourits; Petros Perros; Kostas Boboridis; Antonella Boschi; Nicola Currò; Chantal Daumerie; George J Kahaly; Gerasimos E Krassas; Carol M Lane; John H Lazarus; Michele Marinò; Marco Nardi; Christopher Neoh; Jacques Orgiazzi; Simon Pearce; Aldo Pinchera; Susanne Pitz; Mario Salvi; Paolo Sivelli; Matthias Stahl; Georg von Arx; Wilmar M Wiersinga Journal: Eur J Endocrinol Date: 2008-03 Impact factor: 6.664
Authors: David J Terris; Samuel Snyder; Denise Carneiro-Pla; William B Inabnet; Emad Kandil; Lisa Orloff; Maisie Shindo; Ralph P Tufano; R Michael Tuttle; Mark Urken; Michael W Yeh Journal: Thyroid Date: 2013-09-14 Impact factor: 6.568
Authors: Joseph G Hollowell; Norman W Staehling; W Dana Flanders; W Harry Hannon; Elaine W Gunter; Carole A Spencer; Lewis E Braverman Journal: J Clin Endocrinol Metab Date: 2002-02 Impact factor: 5.958
Authors: T Morita; H Tamai; A Oshima; T Mukuta; S Fukata; K Kuma; L F Kumagai; S Nagataki Journal: J Clin Endocrinol Metab Date: 1990-10 Impact factor: 5.958
Authors: So Young Park; Bo Hyun Kim; Mijin Kim; A Ram Hong; Jun Park; Hyunju Park; Min Sun Choi; Tae Hyuk Kim; Sun Wook Kim; Ho-Cheol Kang; Jae Hoon Chung Journal: Endocrine Date: 2021-04-15 Impact factor: 3.633
Authors: Verena Theiler-Schwetz; Thomas Benninger; Christian Trummer; Stefan Pilz; Markus Reichhartinger Journal: Front Endocrinol (Lausanne) Date: 2022-05-31 Impact factor: 6.055